DE60323677D1 - Verfahren zur bestimmung des wiederauftretens von prostata krebs - Google Patents

Verfahren zur bestimmung des wiederauftretens von prostata krebs

Info

Publication number
DE60323677D1
DE60323677D1 DE60323677T DE60323677T DE60323677D1 DE 60323677 D1 DE60323677 D1 DE 60323677D1 DE 60323677 T DE60323677 T DE 60323677T DE 60323677 T DE60323677 T DE 60323677T DE 60323677 D1 DE60323677 D1 DE 60323677D1
Authority
DE
Germany
Prior art keywords
reproduction
determining
prostate cancer
cancer
evaluating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323677T
Other languages
English (en)
Inventor
Jeffrey S Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60323677D1 publication Critical patent/DE60323677D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
DE60323677T 2003-01-10 2003-12-15 Verfahren zur bestimmung des wiederauftretens von prostata krebs Expired - Lifetime DE60323677D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43920503P 2003-01-10 2003-01-10
PCT/US2003/039864 WO2004063701A2 (en) 2003-01-10 2003-12-15 Methods of diagnosing and treating cancer

Publications (1)

Publication Number Publication Date
DE60323677D1 true DE60323677D1 (de) 2008-10-30

Family

ID=32713451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323677T Expired - Lifetime DE60323677D1 (de) 2003-01-10 2003-12-15 Verfahren zur bestimmung des wiederauftretens von prostata krebs

Country Status (8)

Country Link
US (1) US7771953B2 (de)
EP (1) EP1581794B1 (de)
AT (1) ATE408712T1 (de)
AU (1) AU2003293556A1 (de)
DE (1) DE60323677D1 (de)
ES (1) ES2314272T3 (de)
HK (1) HK1080945A1 (de)
WO (1) WO2004063701A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8548562B2 (en) * 2006-04-04 2013-10-01 John Trachtenberg System and method of guided treatment within malignant prostate tissue
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
EP2727606A3 (de) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
WO2010096486A1 (en) * 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3064945A1 (de) * 2012-02-24 2016-09-07 Cornell University Erhöhter psma-wert als identifikator von tödlichem prostatakrebs
MA41046A (fr) * 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
CN110418802A (zh) 2017-01-20 2019-11-05 朱诺治疗学有限公司 细胞表面缀合物及相关的细胞组合物和方法
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4814275A (en) * 1985-05-13 1989-03-21 E.I. Dupont De Nemours And Company Monoclonal hybridoma antibody specific for a human epithelial antigen
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4863854A (en) * 1985-08-12 1989-09-05 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to mucin-like human differentiation antigens
DE3772785D1 (de) 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
MX174467B (es) * 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
AU593611B2 (en) 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
ZA877727B (en) 1986-10-17 1988-06-29 Cytogen Corp Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4863851A (en) 1986-10-20 1989-09-05 The Upjohn Company Monoclonal antibody to prostate secretory protein
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
CA1306739C (en) 1987-02-16 1992-08-25 Gohfu Suzukamo Solid base, process for preparing the same and use of the same in preparation of internal olefins
US5013645A (en) * 1987-04-14 1991-05-07 Abbott Laboratories Immunological methods and materials for detection of tumor associated antigens
GB9007965D0 (en) 1990-04-09 1990-06-06 Nycomed As Compounds
EP0466200B1 (de) * 1987-07-16 1996-04-24 Nycomed Imaging As Aminocarbonsäure und Derivate
US5531978A (en) * 1987-07-16 1996-07-02 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5130118A (en) * 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) * 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5342924A (en) * 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
GB8801646D0 (en) 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5118611A (en) * 1988-07-25 1992-06-02 Adeza Biomedical Corporation Adenocarcinoma antigen binding methods and reagents
EP0382583B1 (de) 1989-02-10 1996-01-17 Celltech Therapeutics Limited Aza-Macrozyklen und Verfahren zu deren Herstellung
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
DE3911816A1 (de) 1989-04-11 1990-10-25 Hoechst Ag Substituierte 1,4,7,10-tetraazacyclotridecane, verfahren zu deren herstellung sowie verwendung derselben zur markierung von substanzen mit radionukliden
US5378142A (en) * 1991-04-12 1995-01-03 Engelhard Corporation Combustion process using catalysts containing binary oxides
GB9115192D0 (en) 1991-07-12 1991-08-28 Antisoma Ltd Cancer treatment
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0627940B1 (de) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1757694A3 (de) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostata-spezifisches Membranantigen
US5428156A (en) * 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
WO1994026297A1 (en) 1993-05-17 1994-11-24 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
WO1995026206A1 (en) 1994-03-28 1995-10-05 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE69635801T2 (de) 1995-02-24 2006-11-02 Sloan-Kettering Institute For Cancer Research Prostataspezifisches membranes antigen und seine anwendungen
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
CA2223261C (en) 1995-06-07 2010-05-11 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
IL126314A (en) 1996-03-25 2003-07-31 Northwest Biotherapeutics Inc Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5855353A (en) * 1996-05-31 1999-01-05 Owens Corning Fiberglas Technology, Inc. Vibration damping system
US5958474A (en) * 1996-08-21 1999-09-28 Nestec S.A. Process for preparing food flavor precursors
IT1291623B1 (it) 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
WO1999043710A1 (en) 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO2000050457A1 (en) 1999-02-22 2000-08-31 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CA2374001A1 (en) 1999-06-07 2000-12-14 Center For Molecular Medicine And Immunology Alpha or beta emitters attached to fragments in radioimmunotherapy
CA2436408A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto

Also Published As

Publication number Publication date
WO2004063701A2 (en) 2004-07-29
EP1581794B1 (de) 2008-09-17
AU2003293556A1 (en) 2004-08-10
EP1581794A2 (de) 2005-10-05
ES2314272T3 (es) 2009-03-16
US20040214204A1 (en) 2004-10-28
EP1581794A4 (de) 2007-03-28
AU2003293556A8 (en) 2004-08-10
US7771953B2 (en) 2010-08-10
WO2004063701A3 (en) 2006-02-16
HK1080945A1 (en) 2006-05-04
ATE408712T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
DE602004019812D1 (de) Marker für neuromyelitis optica
DE602005025907D1 (de) Verrohrungen und verfahren zur verwendung solcher verrohrungen in unterirdischen zementierungen
DE60226271D1 (de) Verfahren zum nachweis von prostatakrebs
DE602005021336D1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
DE602005023517D1 (de) Verfahren zur bestimmung von genotoxizität
ATE483972T1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
ATE516742T1 (de) Verfahren zur bestimmung der optischen eigenschaften eines mehrschichtigen gewebes
DE602005021839D1 (de) Drehbare Sonde un Verfahren zur Reinigung von Hohlräumen
DE502005002364D1 (de) Verfahren zur bestimmung relevanter objekte
ATE536420T1 (de) Verbesserte verfahren für beaming
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DE602006014679D1 (de) Verfahren zur bestimmung der eisenkonzentration
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
HK1080945A1 (en) Method of determining risk for prostate cancer recurrence
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
DE502005002108D1 (de) Verfahren zur funktionalisierung von biosensor-chips
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
DE112005002199A5 (de) Verfahren und System zur Echtheitsbestimmung der individual-typischen Merkmale von Prüfobjekten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition